KRAS PCR Screening Kit Detects Seven Mutations in a Single Experiment
By LabMedica International staff writers Posted on 02 Feb 2015 |
A research kit designed for use with the latest droplet digital PCR systems is able to detect simultaneously the seven most common KRAS mutations in a single ddPCR experiment.
KRAS mutations are found in 90% of pancreatic cancer cases and 30% of colorectal cancer cases, making it a gene of great interest to cancer researchers. The protein product of the normal KRAS (Kirsten rat sarcoma viral oncogene) gene performs an essential function in normal tissue signaling, and its mutation is an essential step in the development of many cancers. A single amino acid substitution is responsible for the activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas, and colorectal carcinoma.
The new Bio-Rad Laboratories, Inc. (Hercules, CA, USA) ddPCR KRAS Screening Multiplex Kit is able to detect and quantify extremely low levels (down to 0.2%) of KRAS mutant DNA in a single assay. Bio-Rad’s ddPCR technology provides an absolute measure of target DNA molecules without the need for a standard curve. This technology enables detection of a single mutant molecule in a background of 2,000 wild-type molecules (0.05% mutation frequency).
The ddPCR KRAS Screening Multiplex Kit is compatible with all of Bio-Rad’s Droplet Digital PCR Systems, including the new AutoDG instrument. AutoDG creates droplets quickly, reproducibly, and reliably. At maximum capacity, the system can generate droplets for 96 wells in less than 45 minutes. The instrument can generate droplets for fluorescent probe-based or EvaGreen dye-based detection. The AutoDG Instrument has its own hood and HEPA filter, reducing contamination so the system can be used on a standard laboratory bench, without the need for a PCR cabinet or cleanroom.
“The KRAS Screening Multiplex Kit delivers a simple yes/no answer as to whether a KRAS mutation exists in smaller samples,” said Dr. Filip Janku of the University of Texas MD Anderson Cancer Center (Houston, USA). “If researchers were to test for the presence of each possible mutation they could end up performing seven to ten separate PCR experiments only to discover the sample was negative. Multiplex kits such as the KRAS Screening Multiplex Kit allow researchers to screen for multiple mutations in a single reaction, saving time and costly resources.”
Related Links:
Bio-Rad Laboratories, Inc.
University of Texas MD Anderson Cancer Center
KRAS mutations are found in 90% of pancreatic cancer cases and 30% of colorectal cancer cases, making it a gene of great interest to cancer researchers. The protein product of the normal KRAS (Kirsten rat sarcoma viral oncogene) gene performs an essential function in normal tissue signaling, and its mutation is an essential step in the development of many cancers. A single amino acid substitution is responsible for the activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas, and colorectal carcinoma.
The new Bio-Rad Laboratories, Inc. (Hercules, CA, USA) ddPCR KRAS Screening Multiplex Kit is able to detect and quantify extremely low levels (down to 0.2%) of KRAS mutant DNA in a single assay. Bio-Rad’s ddPCR technology provides an absolute measure of target DNA molecules without the need for a standard curve. This technology enables detection of a single mutant molecule in a background of 2,000 wild-type molecules (0.05% mutation frequency).
The ddPCR KRAS Screening Multiplex Kit is compatible with all of Bio-Rad’s Droplet Digital PCR Systems, including the new AutoDG instrument. AutoDG creates droplets quickly, reproducibly, and reliably. At maximum capacity, the system can generate droplets for 96 wells in less than 45 minutes. The instrument can generate droplets for fluorescent probe-based or EvaGreen dye-based detection. The AutoDG Instrument has its own hood and HEPA filter, reducing contamination so the system can be used on a standard laboratory bench, without the need for a PCR cabinet or cleanroom.
“The KRAS Screening Multiplex Kit delivers a simple yes/no answer as to whether a KRAS mutation exists in smaller samples,” said Dr. Filip Janku of the University of Texas MD Anderson Cancer Center (Houston, USA). “If researchers were to test for the presence of each possible mutation they could end up performing seven to ten separate PCR experiments only to discover the sample was negative. Multiplex kits such as the KRAS Screening Multiplex Kit allow researchers to screen for multiple mutations in a single reaction, saving time and costly resources.”
Related Links:
Bio-Rad Laboratories, Inc.
University of Texas MD Anderson Cancer Center
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples